Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley +1 more source
Skeletal Muscle Loss During Neoadjuvant Chemotherapy for Breast Cancer: Diabetes as an Independent Predictor. [PDF]
Sürmeli ZG +9 more
europepmc +1 more source
Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation. [PDF]
Paluri RK +7 more
europepmc +1 more source
A multicenter retrospective study of neoadjuvant chemotherapy and breast conservation rate in locally advanced breast cancer. [PDF]
Abu El-Ela RY +3 more
europepmc +1 more source
Early Ovarian Reserve Depletion During Neoadjuvant Chemotherapy in Female Patients with Bone and Soft Tissue Sarcoma: A Longitudinal Anti-Müllerian Hormone Study. [PDF]
Wang B +6 more
europepmc +1 more source
Baseline and Early-Delta Quantitative Ultrasound Radiomics for Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer. [PDF]
Putin R +5 more
europepmc +1 more source
The influence of preoperative neoadjuvant chemotherapy on the incidence of post-induction hypotension in patients with ovarian cancer- a retrospective observational cohort study. [PDF]
Zhang CY +6 more
europepmc +1 more source
Neoadjuvant chemotherapy and ongoing-trials.
The history of preoperative therapy for gastric carcinoma was outlined here to demonstrate its value in terms of safety and efficacy.The data collected in this review were obtained from studies found in PubMed using the search terms "preoperative chemotherapy", "preoperative radiotherapy", "preoperative chemoradiotherapy", "neoadjuvant treatment", and
D'Ugo, Domenico, Biondi, Alberto
openaire +4 more sources
Related searches:
Neoadjuvant Chemotherapy in Pancreatic Cancer
JAMA Surgery, 2021There is increasing interest in the use of adjuvant treatment for pancreatic cancer since although postoperative mortality is much improved, median long-term survival is only on the order of 11–15 mo. Despite a proliferation of studies in advanced pancreatic cancer indicating a benefit for chemotherapy, there has only been one small randomized adjuvant
Ankit, Jain +2 more
openaire +4 more sources

